Efficacy and Treatment Resistance Factors of 79 Psoriasis Patients Treated with Apremilast

DOI Web Site
  • Usui Toshihiro
    Department of Dermatology, St. Luke's International Hospital
  • Zenke Yukari
    Department of Dermatology, St. Luke's International Hospital
  • Arai Satoru
    Department of Dermatology, St. Luke's International Hospital

Bibliographic Information

Other Title
  • アプレミラスト治療を行った乾癬患者79例の解析
  • アプレミラスト チリョウ オ オコナッタ カンセンカンジャ 79レイ ノ カイセキ

Search this article

Description

<p>Apremilast is an orally administered small-molecule inhibitor of phosphodiesterase 4 approved for the treatment of psoriasis vulgaris. However, it is not clear which type of psoriasis patients are treated more effectively with Apremilast. Herein, we examined the efficacy and treatment resistance factors of Apremilast in 79 patients with psoriasis vulgaris. At 16 weeks after Apremilast administration, 20 of 61 patients (32.8%) achieved improvement in psoriasis area and severity index (PASI) -75. Among all cases, 37 small plaque types and 42 large plaque types were included. In large plaque type patients, the frequencies of BMI >25 and side effects were significantly higher than in those with small plaque types, although there was no difference in PASI improvement between the two groups.</p><p>In conclusion, Apremilast was effective for psoriasis patients, regardless of plaque size or incidence of adverse events.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top